SciELO - Scientific Electronic Library Online

 
vol.19 issue2Evaluation of the nutritive value of sugarcane residues inoculated with fungus Fomes sp author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Revista MVZ Córdoba

Print version ISSN 0122-0268

Rev.MVZ Cordoba vol.19 no.2 Córdoba May/Aug. 2014

 

EDITORIAL

Virus Chikungunya in Colombia, a simple matter of time?

¿Virus Chikungunya en Colombia, simple cuestión de tiempo?

Chikungunya virus (CHIKV) is an RNA alphavirus of the family Togaviridae. The alphaviruses consist of 29 species, including eastern, western, and Venezuelan equine encephalitis viruses among others. CHIKV is transmitted by vector mosquitoes, Aedes aegypti and Aedes albipictus, which are abundant in the South American tropics.

CHIKV was first isolated in 1953 in the serum of a patient in Tanzania during an epidemic of dengue. In a recent dendrogram, this isolate appeared with the name of Ross low psg (1,2). The first clinical report of chikungunya was in Thailand between 1962 and 1964 (3). Between 1960 and 2003 CHIKV reemerged and spread in Southeast Asian countries such as India, Malaysia, Indonesia, Vietnam, and Thailand, among others. A Central African genotype has occurred since 2000 and spread to Europe, Asia, and Australia (4). From the clinical perspective, CHIKV may produce acute, sub-acute, or chronic illness. The acute phase is characterized by an abrupt onset with fever surpassing 39°C and severe joint pain. Polyarthralgia, headache, myalgia, back pain, nausea, vomiting, rash, and conjunctivitis are common; the duration of the acute phase is 3 to 10 days (5). Symptoms of CHIKV infection are similar to dengue.

The inevitable arrival of CHIKV in America occurred on 5 December 2013, when the first indigenous case appeared on the Caribbean island Saint Martin in the French West Indies. On 20 December, 50 cases were confirmed on the island of Martinique; in January 2014 CHIKV rapidly disseminated to the islands of Guadeloupe, Saint Barthelemy, Dominica and the British Virgin Islands. (1). In Rio de Janeiro, Brazil, an imported case was reported in a patient who had visited Sumatra, indicating the high potential for spread of the virus by imported patients bitten by local mosquitoes (6).

The vector of CHIKV was initially believed to be only Aedes aegypti; however, the virus was also adapted to Aedes albipictus, Ae. Vittatus, and Anopheles stephensi. The change of vector represents a surprising evolutionary adaptation that involved a mutation in the viral envelope that facilitates replication. The genus Aedes has a wide rural and urban distribution in Colombia and specifically in the Caribbean area, which could facilitate the introduction and subsequent endemicity of CHIKV simply and naturally. It follows that Colombian health authorities should identify aircraft and boats from Venezuela and the Caribbean and fumigate holds before removing cargo and baggage. We do not know the ultimate outcome of competition of CHIKV and Dengue virus in a single vector. Nor do we know whether CHIKV will have an enzootic cycle as in Africa and Asia, or a sylvatic cycle in primates and other vertebrates of the Caribbean region by which it could enter Colombia, as West Nile virus did a few years ago.

The introduction of a new pathogen in Colombia poses more challenges than dengue. The impact of CHIKV in other countries has been worse than dengue, causing lengthy absenteeism from work and disabling symptoms (arthritis, arthralgia) that can last for weeks or months. We do not know if this visiting virus has virulence factors that could transform it into a hemorrhagic virus; we only know that CHIKV is very close to the Asian strains isolated in China in 2012, and the Philippines in 2013.

As seen of other emerging and re-emerging viruses, the arrival of the CHIKV in Colombia is simply a matter of time (currently in Venezuela). We must prepare ourselves for a new differential diagnosis and assume from now on the clinical and eco-epidemiological surveillance.

Marco González T. M.Sc.

Salim MAttar V. Ph.D.


REFERENCES

1. Isabelle Leparc-Goffart, Antoine Nougairede, Sylvie Cassadou, Christine Prat, Xavier de Lamballerie. Chikungunya in the Americas, LANCET 2014; 383:514.         [ Links ]

2. Leparc-Goffart I, Nougairede A, Cassadou S, C Prat, Lamballerie X. Chikungunya in the Americas. Lancet 2014; 383: 514.         [ Links ]

3. Suchitra Nimmannitya, Scott B. Halstead, Sanford N. Cohen, Mark R. Margiotta. Observations on Hospitalized Patients with Hemorrhagic Fever. Am J Trop Med Hyg November 1969; 18:954-971.         [ Links ]

4. Powers A, Logue C. Changing patterns of chikungunya virus: re-emergence of a zoonotic Arboviruses. J Gen Virol 2007; 88, 2363-2377.         [ Links ]

5. OPS/CDC. Preparación y respuesta ante la eventual introducción del virus chikungunya en las Americas. Washington, DC; Organización Panamericana de la Salud; Centers for Disease Control and Prevention: 2011.         [ Links ]

6. Gomes CA, Marandino R, Pimentel MA, Ribeiro NR.Chikungunya virus infection: report of the first case diagnosed in Rio de Janeiro, Brazil. Revista da Sociedade Brasileira de Medicina Tropical 2012; 45(1):128-129.         [ Links ]